Table 1.
Baseline information of the included patients with node positive CGA, n (%)
| Groups | Training set (n=723) |
Validating set (n=315) |
P value |
| Sex | |||
| Male | 596 (82.43) | 261 (82.86) | 0.939 |
| Female | 127 (17.57) | 54 (17.14) | |
| Age (years) | |||
| <70 | 490 (67.77) | 210 (66.67) | 0.781 |
| ≥70 | 233 (32.23) | 105 (33.33) | |
| Race | |||
| White | 628 (86.86) | 268 (85.08) | 0.437 |
| Black | 40 (5.53) | 24 (7.62) | |
| Others | 55 (7.61) | 23 (7.30) | |
| Tumour size | |||
| <5 cm | 442 (61.13) | 186 (59.05) | 0.573 |
| ≥5 cm | 281 (38.87) | 129 (40.95) | |
| Grade | |||
| I–II | 279 (38.59) | 119 (37.78) | 0.859 |
| III–IV | 444 (61.41) | 196 (62.22) | |
| T stage | |||
| T1a | 17 (2.35) | 4 (1.27) | 0.224 |
| T1b | 53 (7.33) | 20 (6.35) | |
| T2 | 83 (11.48) | 42 (13.33) | |
| T3 | 501 (69.29) | 216 (68.57) | |
| T4a | 49 (6.78) | 28 (8.89) | |
| T4b | 20 (2.77) | 5 (1.59) | |
| N stage | |||
| N1 | 332 (45.92) | 147 (46.67) | 0.921 |
| N2 | 229 (31.67) | 101 (32.06) | |
| N3 | 162 (22.41) | 67 (21.27) | |
| M stage | |||
| M0 | 678 (93.78) | 285 (90.48) | 0.079 |
| M1 | 45 (6.22) | 30 (9.52) | |
| Low nodes yield | |||
| Yes | 532 (73.58) | 243 (77.14) | 0.300 |
| No | 191 (26.42) | 72 (22.86) | |
| No. of nodes harvest | 17 (12, 25) | 16 (11, 24) | 0.400 |
| No. of positive nodes | 3 (1, 6) | 3 (1, 6) | 1.000 |
| Median survival (months) | 28 (25, 32) | 25 (21, 32) | 0.361 |
| CSS rate (%) | |||
| 1 year | 77.0 (74.0, 80.2) | 76.3 (71.6, 81.2) | |
| 2 years | 53.7 (50.1, 57.5) | 51.4 (46.0, 57.5) | |
| 5 years | 30.3 (26.7, 34.5) | 26.4 (20.9, 33.4) |
CGA, cardia gastric adenocarcinoma; CSS, cancer-specific survival.